Business Wire

Sysmex and LabCorp Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products to Support the Development of Precision Medicine in Oncology

The Sysmex OncoBEAM™ and Plasma Sequencing assays allow for molecular genetic analysis of cell-free tumor DNA from blood samples. These technologies, often referred to as liquid biopsies, provide ...
Business Insider

Sysmex Inostics' OncoBEAM™ Liquid Biopsy Technology Demonstrates Utility for Clinical Management of Melanoma Patients Undergoing Treatment With Targeted Therapy and Immune ...

HAMBURG, Germany, Oct. 15, 2018 /PRNewswire/ -- Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce ...
PR Newswire

Sysmex Signs Supply and Distribution Agreement with Streck

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that Sysmex Corporation has signed a worldwide supply and distribution agreement with Streck, Inc. The agreement allows Sysmex to ...
PR Newswire

Sysmex Inostics OncoBEAM™ Circulating Tumor DNA Technology Demonstrates Superior Response Prediction for Advanced Pancreatic Cancer over Standard-of-care Protein Biomarkers

Recent data published in Annals of Oncology from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution ...
FierceBiotech

Sysmex and LabCorp Announce a Strategic Collaboration for Blood-Based Molecular Testing Services and Products to Support the Development of Precision Medicine in Oncology

KOBE, Japan & BURLINGTON, N.C. -- Sysmex Corporation (TSE:6869) and Laboratory Corporation of America ® Holdings (LabCorp®) (LH:NYSE) today announced a strategic collaboration focused on the ...